SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after a patent infringement lawsuit from Novo Nordisk and FDA scrutiny led the company to halt its oral semaglutide pill offering. The community is sharply divided, with many fearing bankruptcy and further declines due to regulatory and legal challenges, while others view it as an oversold "short squeeze" candidate given its strong core business.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending as its S-4 registration for the Infleqtion merger is effective, setting a February 12 shareholder vote and a ticker change to INFQ by February 17. The community is buzzing about Infleqtion's quantum technology, new contracts with NASA and the Department of Energy, and its perceived undervaluation compared to quantum peers, with many anticipating a significant post-merger rally.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors celebrate its announced Q4 profitability and reiteration of a 2026 annual profit target, alongside reaching 100 million battery swaps. Despite a minor software recall and a perceived manipulative analyst downgrade, the community is buzzing with anticipation of a significant short squeeze, believing the stock is deeply undervalued given its improving fundamentals and unique battery-swapping technology.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab (SCHW) is trending as the broader financial advisory sector reacts to fears that a new AI tax strategy tool from Altruist could disrupt traditional wealth management services and compress fees. The community is debating if this selloff is an overreaction or a legitimate threat, with many viewing it as a "buy the dip" opportunity for established firms to quickly adapt.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing a sharp rally driven by positive Phase 2a trial results for its atopic dermatitis drug, EVO301, which met its primary efficacy endpoint. The positive data has led to significant analyst price target raises, sparking widespread community discussion around its upside potential and short squeeze dynamics.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility after its Q4 earnings report, which revealed a revenue miss and conservative guidance despite overall profitability, sparking a heated debate among investors. While many believe the stock's sharp decline is an overreaction driven by market manipulation and short interest, others express deep frustration over its continued downward trend amidst broader fintech sector weakness.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is surging after reporting a blockbuster Q4, driven by record user growth, increased premium subscribers, and improved profitability, fueling widespread bullish sentiment and discussions of a potential short squeeze.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending after its Q4 report showed strong revenue and GMV growth with significantly reduced losses, setting a clear path to profitability. The community is actively debating a "sell the news" reaction despite strong fundamentals and increasing analyst optimism for the "Amazon of Africa" narrative.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart's imminent earnings report is sparking intense debate among investors, with strong convictions for both significant upside and downside moves. The community is also closely watching how potential credit card interest rate caps and the broader fintech market could influence the AI-powered lending platform's outlook.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Robust positive 52-week maintenance data for Nektar Therapeutics' atopic dermatitis drug, rezpegaldesleukin, is driving significant analyst upgrades and community discussions around a major valuation re-rate, given its durable responses and strong safety profile. Investors are also actively speculating on a potential short squeeze or a significant settlement/buyout, particularly with ongoing litigation with Lilly.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deep Dive Into Roivant Sciences Stock: Analyst Perspectives (4 Ratings)

Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 25.4% during the third quarter, according to its most recent disclosure with...

Roivant Sciences (NASDAQ:ROIV) Reaches New 1-Year High - Still a Buy?

Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High - What's Next...

Roivant Sciences Q3 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the...

Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in...

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity.</li><li>The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo.</li><li>Following discussions with the U.S. Food and Drug Administration, Roivant’s subsidiary,&nbsp;Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026.</li></ul>Roivant Sciences (ROIV) on Friday reported encouraging Phase 2 clinical results for its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis, while also releasing its fiscal third quarter (Q3) earnings.&nbsp;The company reported a Q3 revenue of $1.9 million and a loss per share (EPS) of $0.38. Revenue came in below the analysts’ consensus estimate of $6.14 million, while EPS surpassed the consensus, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Positive BEACON Trial Outcomes&nbsp;</h2>In the BEACON study, patients receiving the higher 45 mg dose of brepocitinib saw substantial reductions in skin disease activity compared with placebo, demonstrating statistically meaningful benefits as early as four weeks and maintained through week 16.The trial enrolled 31 participants across U.S. clinical sites and tested two dose levels against a placebo. Despite including the most treatment-resistant patients, the highest-dose group achieved rapid and sustained improvement.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ROIV">Roivant stock</a> traded over 9% higher in Friday’s pre-market.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘normal’ message volume levels.&nbsp;<h2 class="st-heading-2">Updates On Subsidiaries’ Therapy Programs</h2>Following discussions with the U.S. Food and Drug Administration (FDA), Riovant’s subsidiary, Priovant, plans to launch a pivotal Phase 3 study in cutaneous sarcoidosis in 2026. The company has already submitted a New Drug Application for brepocitinib in dermatomyositis and expects additional Phase 3 data in non-infectious uveitis during the second half of 2026.Additionally, the company said Immunovant’s IMVT-1402 program is fully enrolled in a late-stage rheumatoid arthritis study, with results anticipated in 2026.&nbsp;Meanwhile, the firm’s subsidiary Pulmovant’s&nbsp;mosliciguat trial in pulmonary hypertension linked to interstitial lung disease is also fully enrolled.As of Dec. 31, 2025, Roivant reported approximately $4.5 billion in cash andequivalents.ROIV stock has gained over 94% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-looks-to-end-a-five-day-losing-streak-retail-believes-the-next-growth-wave-is-unfolding-now/cZbFfdXR4nD">Nvidia Looks To End A Five-Day Losing Streak – Retail Believes ‘The Next Growth Wave Is Unfolding Now’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Roivant Sciences logo is seen displayed on a smartphone screen.

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 

Equity

The company reported the Phase 2 clinical results for its experimental oral therapy brepocitinib, along with third-quarter financial data. 


Insights into Roivant Sciences Q3 Earnings

Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) will be releasing its Q3 2026 earnings before the market opens on Friday, February 6. (View Earnings Report at...

Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV

Parkside Financial Bank & Trust trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 46.7% in the third quarter, according to its most recent Form 13F filing with the Securities...

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Current Price	$27.31
Prev Close	$27.67
Open	$27.42
Dividend Yield	0.00%
50-Day Moving Average	$22.11
Beta	0.89
Avg. Volume	5.73M
PE Ratio	-23.68

52-Week High	$27.72
52-Week Low	$8.73
Market Capitalization	$19.8B
EPS (Annual)	-$0.2371
Price to Book	4.60
Revenue Per Employee	$38,737.33
Enterprise Value/EBITDA	N/A

ROIV
Roivant Sciences Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ROIV News

ROIVRoivant Sciences Ltd